AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has earned an average rating of “Hold” from the seventeen analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $25.11.

A number of analysts have recently issued reports on the stock. ValuEngine raised shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Cantor Fitzgerald reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. BidaskClub raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Finally, Deutsche Bank AG set a $24.00 price objective on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th.

Several large investors have recently modified their holdings of AMAG. BlackRock Inc. boosted its position in shares of AMAG Pharmaceuticals by 67,790.9% during the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after acquiring an additional 4,988,054 shares during the last quarter. State Street Corp boosted its position in shares of AMAG Pharmaceuticals by 75.2% during the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after acquiring an additional 1,082,366 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of AMAG Pharmaceuticals by 152.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after acquiring an additional 619,370 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of AMAG Pharmaceuticals by 162.2% during the first quarter. Goldman Sachs Group Inc. now owns 607,980 shares of the specialty pharmaceutical company’s stock worth $13,710,000 after acquiring an additional 376,139 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its position in shares of AMAG Pharmaceuticals by 175.1% during the second quarter. Robeco Institutional Asset Management B.V. now owns 525,989 shares of the specialty pharmaceutical company’s stock worth $9,679,000 after acquiring an additional 334,811 shares during the last quarter.

AMAG Pharmaceuticals (NASDAQ AMAG) traded down 0.462% on Thursday, reaching $16.175. 417,257 shares of the company were exchanged. The firm has a 50-day moving average of $18.44 and a 200 day moving average of $19.11. The firm’s market capitalization is $570.78 million. AMAG Pharmaceuticals has a 12-month low of $15.78 and a 12-month high of $36.83.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.45 earnings per share. On average, equities analysts predict that AMAG Pharmaceuticals will post ($1.38) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/19/amag-pharmaceuticals-inc-amag-given-consensus-recommendation-of-hold-by-analysts.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.